Table 1. Snapshot of North America Multiple Sclerosis Drugs Market in Balanced Perspective, 2020-2027 17
Table 2. Growth Rate of World GDP, 2020-2022 21
Table 3. World Health Spending by Region, $ bn, 2013-2020 28
Table 4. Price Comparison of Commonly Used Multiple Sclerosis Medications 31
Table 5. Main Adverse Effects of Multiple Sclerosis Drugs 32
Table 6. Main Product Trends and Market Opportunities in North America Multiple Sclerosis Drugs Market 33
Table 7. North America Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn 41
Table 8. North America Multiple Sclerosis Drugs Market: Immunomodulators by Drug, 2017-2027, $ mn 44
Table 9. North America Multiple Sclerosis Drugs Market: Immunosuppressants by Drug, 2017-2027, $ mn 46
Table 10. North America Multiple Sclerosis Drugs Market by Drug Class, 2017-2027, $ mn 47
Table 11. North America Multiple Sclerosis Drugs Market by Drug Category, 2017-2027, $ mn 58
Table 12. North America Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn 62
Table 13. North America Multiple Sclerosis Drugs Market by MS Type, 2017-2027, $ mn 66
Table 14. North America Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn 72
Table 15. North America Multiple Sclerosis Drugs Market by Country, 2017-2027, $ mn 78
Table 16. U.S. Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn 82
Table 17. U.S. Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn 82
Table 18. U.S. Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn 82
Table 19. Canada Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn 84
Table 20. Canada Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn 84
Table 21. Canada Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn 84
Table 22. Mexico Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn 86
Table 23. Mexico Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn 86
Table 24. Mexico Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn 86
Table 25. Abbvie, Inc.: Company Snapshot 91
Table 26. Abbvie, Inc.: Business Segmentation 91
Table 27. Abbvie, Inc.: Product Portfolio 92
Table 28. Abbvie, Inc.: Revenue, 2017-2019, $ mn 92

LIST OF FIGURE

Figure 1. Research Method Flow Chart 11
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 14
Figure 3. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2020-2027 16
Figure 4. North America Multiple Sclerosis Drugs Market, 2017-2027, $ mn 19
Figure 5. Impact of COVID-19 on Business 22
Figure 6. Primary Drivers and Impact Factors of North America Multiple Sclerosis Drugs Market 24
Figure 7. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 27
Figure 8. World Population 65 and Over, % of Total Population, 1950-2060 27
Figure 9. Primary Restraints and Impact Factors of North America Multiple Sclerosis Drugs Market 29
Figure 10. Investment Opportunity Analysis 34
Figure 11. Porters Fiver Forces Analysis of North America Multiple Sclerosis Drugs Market 37
Figure 12. Breakdown of North America Multiple Sclerosis Drugs Market by Drug Type, 2020-2027, % of Revenue 41
Figure 13. Contribution to North America 2021-2027 Cumulative Revenue by Drug Type, Value ($ mn) and Share (%) 42
Figure 14. North America Multiple Sclerosis Drugs Market: Immunomodulators, 2017-2027, $ mn 43
Figure 15. North America Multiple Sclerosis Drugs Market: Immunosuppressants, 2017-2027, $ mn 45
Figure 16. Breakdown of North America Multiple Sclerosis Drugs Market by Drug Class, 2020-2027, % of Revenue 48
Figure 17. Contribution to North America 2021-2027 Cumulative Revenue by Drug Class, Value ($ mn) and Share (%) 48
Figure 18. North America Multiple Sclerosis Drugs Market: Monoclonal Antibodies, 2017-2027, $ mn 49
Figure 19. North America Multiple Sclerosis Drugs Market: Interferon Beta, 2017-2027, $ mn 50
Figure 20. North America Multiple Sclerosis Drugs Market: Sphingosine 1 Phosphate Receptor Modulators, 2017-2027, $ mn 51
Figure 21. North America Multiple Sclerosis Drugs Market: Mixed Polymers, 2017-2027, $ mn 52
Figure 22. North America Multiple Sclerosis Drugs Market: NF-?B Inhibitor, 2017-2027, $ mn 53
Figure 23. North America Multiple Sclerosis Drugs Market: Pyrimidine Synthesis Inhibitor, 2017-2027, $ mn 54
Figure 24. North America Multiple Sclerosis Drugs Market: Corticosteroids, 2017-2027, $ mn 55
Figure 25. North America Multiple Sclerosis Drugs Market: Adrenocorticotropic Hormone, 2017-2027, $ mn 56
Figure 26. North America Multiple Sclerosis Drugs Market: Other Drug Classes, 2017-2027, $ mn 57
Figure 27. Breakdown of North America Multiple Sclerosis Drugs Market by Drug Category, 2020-2027, % of Revenue 58
Figure 28. Contribution to North America 2021-2027 Cumulative Revenue by Drug Category, Value ($ mn) and Share (%) 59
Figure 29. North America Multiple Sclerosis Drugs Market: Large-molecule Drugs, 2017-2027, $ mn 60
Figure 30. North America Multiple Sclerosis Drugs Market: Small-molecule Drugs, 2017-2027, $ mn 61
Figure 31. Breakdown of North America Multiple Sclerosis Drugs Market by Route of Administration, 2020-2027, % of Revenue 62
Figure 32. Contribution to North America 2021-2027 Cumulative Revenue by Route of Administration, Value ($ mn) and Share (%) 63
Figure 33. North America Multiple Sclerosis Drugs Market: Oral Administration, 2017-2027, $ mn 64
Figure 34. North America Multiple Sclerosis Drugs Market: Parenteral Administration, 2017-2027, $ mn 65
Figure 35. Breakdown of North America Multiple Sclerosis Drugs Market by MS Type, 2020-2027, % of Revenue 66
Figure 36. Contribution to North America 2021-2027 Cumulative Revenue by MS Type, Value ($ mn) and Share (%) 67
Figure 37. North America Multiple Sclerosis Drugs Market: Relapsing-remitting MS (RRMS), 2017-2027, $ mn 68
Figure 38. North America Multiple Sclerosis Drugs Market: Primary-progressive MS (PPMS), 2017-2027, $ mn 69
Figure 39. North America Multiple Sclerosis Drugs Market: Secondary-progressive MS (SPMS), 2017-2027, $ mn 70
Figure 40. North America Multiple Sclerosis Drugs Market: Progressive-relapsing MS (PRMS), 2017-2027, $ mn 71
Figure 41. Breakdown of North America Multiple Sclerosis Drugs Market by Distribution Channel, 2020-2027, % of Revenue 72
Figure 42. Contribution to North America 2021-2027 Cumulative Revenue by Distribution Channel, Value ($ mn) and Share (%) 73
Figure 43. North America Multiple Sclerosis Drugs Market: Hospital Pharmacies, 2017-2027, $ mn 74
Figure 44. North America Multiple Sclerosis Drugs Market: Retail Pharmacies, 2017-2027, $ mn 75
Figure 45. North America Multiple Sclerosis Drugs Market: Online Pharmacies, 2017-2027, $ mn 76
Figure 46. Breakdown of North America Multiple Sclerosis Drugs Market by Country, 2020 and 2027, % of Revenue 78
Figure 47. Contribution to North America 2021-2027 Cumulative Revenue by Country, Value ($ mn) and Share (%) 79
Figure 48. U.S. Multiple Sclerosis Drugs Market, 2017-2027, $ mn 81
Figure 49. Canada Multiple Sclerosis Drugs Market, 2017-2027, $ mn 83
Figure 50. Multiple Sclerosis Drugs Market in Mexico, 2017-2027, $ mn 85
Figure 51. Growth Stage of North America Multiple Sclerosis Drugs Industry over the Forecast Period 87